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Abstract 
 
Aldosterone is the main mineralocorticoid hormone controlling sodium balance, fluid 
homeostasis and blood pressure by regulating sodium reabsorption in the Aldosterone 
Sensitive Distal Nephron (ASDN). Germline loss-of-function mutations of the 
mineralocorticoid receptor (MR) in humans and in mice lead to the “renal” form of type 1 
pseudohypoaldosteronism (PHA-1), a case of aldosterone resistance characterized by salt 
wasting, dehydration, failure to thrive, hyperkalemia and metabolic acidosis. To investigate 
the importance of MR in adult epithelial cells, we generated nephron-specific MR knockout 
mice (MRPax8/LC1) using a doxycycline inducible system. Under standard diet, MRPax8/LC1 mice 
exhibit inability to gain weight and significant weight loss compared to control mice. 
Interestingly, despite failure to thrive, MRPax8/LC1 mice survive but develop a severe PHA-1 
phenotype with higher urinary Na+ levels, decreased plasma Na+, hyperkalemia and higher 
levels of plasma aldosterone. This phenotype further worsens and becomes lethal under a 
sodium-deficient diet. NCC protein expression and its phosphorylated form are 
downregulated in the MRPax8/LC1 knockouts, as well as the αENaC protein expression level, 
whereas the expression of glucocorticoid receptor (GR) is increased. A diet rich in Na+ and 
low in K+ does not restore plasma aldosterone to control levels, but is sufficient to restore 
body weight, plasma and urinary electrolytes. In conclusion, MR deletion along the nephron 
fully recapitulates the features of severe human PHA-1 and indicates that ENaC protein 
expression is dependent on MR expression and there are no compensatory mechanisms 
occurring. Hyperkalemia dominates the hypovolemic stimulus even at the expense of 
increased sodium loss. 
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Abbreviation list 
 
ASDN: aldosterone sensitive distal nephron 
MR: mineralocorticoid receptor 
GR: glucocorticoid receptor 
ENaC: epithelial sodium channel 
NCC: Na+ / Cl- co-transporter 
AQP2: Aquaporin 2 
Hsd11b2: 11β-hydroxysteroid dehydrogenase type 2 
PHA-1: type 1 pseudohypoaldosteronism 
RAAS: Renin-Angiotensin-Aldosterone System 
PCT: proximal convoluted tubule 
PST: proximal straight tubule 
TAL: thick ascending limb 
DCT: distal convoluted tubule 
CNT: connecting tubule 
CCD: cortical collecting duct 
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Introduction 
 
MR is expressed in Na+ transporting epithelia such as kidney and colon [11,21], but also in 
nonepithelial tissues (e.g. heart [20], vessels and brain [15,19,16]). Several inactivating 
autosomal dominant mutations of the MR gene (NR3C2) are the principal cause of renal and 
sporadic type 1 PHA which is a rare form of mineralocorticoid resistance characterized by 
neonatal renal salt wasting, failure to thrive, hyponatremia, hyperkalemia, and metabolic 
acidosis, accompanied by extremely high values of plasma renin and aldosterone levels. The 
severe and systemic form of PHA-1 is due to recessive mutations in the genes encoding for 
the three subunits of the epithelial sodium channel (ENaC) (MIM 600228; MIM 600760; 
MIM 600761). Germline MR-deficient mice present a normal prenatal development, but die 
within 8-12 days after birth from a salt-losing syndrome resembling the human PHA-1. They 
display hyponatremia, hyperkalemia, hypovolemia and activation of the Renin-Angiotensin- 
Aldosterone System (RAAS) with a strong increase in renin, angiotensin II, and aldosterone 
plasma concentrations. A strong reduction of the activity of ENaC in colon and kidney was 
also reported [5]. Interestingly, this phenotype can be rescued by subcutaneous injections of 
NaCl, although the animals retain their Na+-losing defect [7]. Inactivation of MR in the 
principal cells of the late connecting tubule (CNT) and of the collecting duct (CD) driven by 
the aquaporin 2 (AQP2) promoter can be compensated under a standard sodium diet, but not 
under a low-sodium diet [23]. This mild phenotype only partially recapitulates the severe 
human PHA-1 phenotype observed under standard salt diet and was explained by long term 
compensatory mechanisms [23]. The same authors used a tamoxifen-inducible strategy to 
delete MR partially within the CNT and cortical collecting ducts (CCD) during adulthood. 
Again, only under a low-salt diet and at adult stage, the induced ablation of MR recapitulates 
the renal sodium wasting observed in mice with constitutive early-onset MR ablation, but not 
hyperkalemia and/or increased mortality [24]. This was explained by compensatory 
mechanisms either by upregulation of sodium transporters upstream of the CNT i.e. the distal 
convoluted tubule 2 (DCT2) where ENaC and the Na+ / Cl- co-transporter (NCC) are co- 
expressed [25], or by upregulation of ENaC-independent, non electrogenic sodium chloride 
transporters expressed along the CD [10]. To address this question, we developed an inducible 
renal tubule-specific MR knockout adult mouse model. Although MRPax8/LC1 mice survive 
under a standard salt diet, they present with a severe renal PHA-1 phenotype characterized by 
increased weight loss, Na+ excretion, hyponatremia, hyperkalemia, high plasma aldosterone 
levels, and failure to thrive. Our data clearly show that MR expression along the nephron and 
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in the collecting duct system during adulthood is crucial for Na+ and K+ homeostasis, and its 
deletion cannot be compensated neither by sodium transporters including ENaC, nor by GR 
upregulation, but solely by a high Na+ and low K+ rescue diet. 
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Methods 
 
Ethical approval 
 
Animal maintenance and all experimental procedures in mice were in accordance with the 
Swiss federal guidelines and were approved by the veterinarian local authorities (“Service de 
la consommation et des affaires vétérinaires”) of the Canton de Vaud, Switzerland. Mice were 
kept in the animal facility under animal care regulations of the University of Lausanne. They 
were housed in groups of up to 5 in ventilated cages in a temperature- (23±1°C) and 
humidity-controlled room with an automatic 12-hour light/dark cycle. All animals had free 
access to laboratory chow and the water was supplied ad libitum. Data origin from both male 
and female animals. Experiments were performed in 3-week-old animals unless differently 
stated. 
Generation of inducible renal tubule-specific MRPax8/LC1 KO mice 
 
Mice lacking MR all along the nephron and in the collecting duct system of the kidney were 
generated by using the Pax8-rtTA transgenic mouse line. Triple-transgenic conditional 
nephron-specific knockouts Nr3c2lox/lox;Pax8-rtTAtg/0;TRE-LC-1tg/0 (MRPax8/LC1) and control 
littermates Nr3c2lox/lox;Pax8-rtTAtg/0 (MRPax8), Nr3c2lox/lox;TRE-LC-1tg/0 (MRLC1) and 
Nr3c2lox/lox (MRlox) were obtained by breeding Nr3c2lox/lox;Pax8-rtTAtg/0 mice with 
Nr3c2lox/lox;TRE-LC-1tg/0. Nr3c2 deletion was induced in renal tubular cells upon doxycycline 
hydrochloride treatment (Sigma, Deisenhofen, Germany) (2 mg/ml and 2% sucrose in the 
drinking water) for 15 days in 4-week-old Nr3c2lox/lox;Pax8-rtTAtg/0;TRE-LC-1tg/0 knockout 
and Nr3c2lox/lox;Pax8-rtTAtg/0, Nr3c2lox/lox;TRE-LC-1tg/0 and Nr3c2lox/lox control mice. 
Genotyping 
 
DNA was recovered and extracted from mouse biopsies. Genotyping by PCR analysis was 
performed using the following primers: Pax8-rtTA: ST1 sense (5’- 
CCATGTCTAGACTGGACAAGA-3’); ST2 antisense (5’- 
CTCCAGGCCACATATGATTAG-3’); LC-1: Cre3 sense (5’- 
TCGCTGCATTACCGGTCGATGC-3’); Cre4 antisense (5’- 
CCATGAGTGAACGAACCTGGTCG-3’); Myogenin: 50S sense (5’- 
TTACGTCCATCGTGGACAGC-3’); 51S antisense (5’-TGGGCTGGGTGTTAGTCTTA- 
3’). Primers for myogenin served as a control for DNA integrity. The PCR program for Pax8- 
rtTA, LC-1 and Myogenin was the following: 37 cycles, each run consisted of 1 minute each 
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at 94°C, 56°C and 72°C. The knockout band corresponding to the recombination of the floxed 
Nr3c2 allele and thus MR deletion in the kidney was detected by PCR on whole kidney using 
the following primers: MR/Nr3c2: MRflox-1 sense (5’-CTCGAGATCTGAACTCCAGGCT- 
3’); MRflox-2 antisense (5’-CCTAGAGTTCCTGAGCTGCTGA-3’); MRflox-3 antisense 
(5’-TAGAAACACTTCGTAAAGTAGAGCT-3’). The PCR program for MR/Nr3c2 was the 
following: 35 cycles, each run consisted of 30 seconds at 95°C followed by 1 minute at 63°C 
and 1 minute at 72°C. 
Quantitative RT-PCR on Kidney Samples 
 
At the end of the experimentation mouse kidneys were isolated, frozen in liquid nitrogen and 
stored at -80°C. A Tissue-Lyser machine (Quiagen) was used to homogenize kidney’s tissues. 
RNA was extracted from the lysed tissues using the guanidnium thiocyanate-phenol- 
chloroform extraction method (QIAzol lysis reagent, QUIAGEN) and its concentration and 
quality were measured and evaluated by the Nano Drop (Witec Ag ND-1000 
Spectrophotometer). Then, the extracted RNA was used and cDNA was synthetized by retro- 
transcription using the PrimeScript RT reagent Kit (Takara Bio Inc, Japan). To quantify the 
relative mRNA expression of MR, 11β-HSD2 and Ren-1c, a Real-timePCR (Taq Man) was 
performed using Applied Biosystems 7500 (Foster City, CA). Primer and probe mixes 
(Mm01241592_mH for MR; Mm01251104_m1 for 11β-HSD2; Mm02342887_mH for Ren- 
1c; 4352341E for β-Actin) and the Taqman Gene Expression Master Mix were purchased and 
used according to the manufacturer’s instructions (Applied Biosystem, Foster City, CA). Each 
measurement was performed in duplicate. For each mRNA transcript detection and the control 
β-Actin, the cDNA, the primers and the probe were mixed and aliquoted together into the 
TaqMan Universal PCR Master mix (Applied Biosystem). Quantification of fluorescence was 
normalized to β-Actin fluorescence to quantify the relative mRNA transcripts expression in 
whole kidney. 
Western Blot Analysis 
 
Freshly isolated kidneys were homogenized by using the polytron. Homogenates were 
centrifuged for 10 minutes at 4°C at 11000 rpm. The supernatant was taken and protein 
concentration was measured by the Bradford method. Protein extracts from whole kidney 
were subjected to Western blot analysis. The proteins were loaded and separated on 10% 
polyacrylamide gels by SDS-PAGE, subjected to a constant electric current of 25 mA in 
running buffer 1x. Then the proteins were transferred onto a PVDF (Perkin Elmer, Boston, 
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MA) or nitrocellulose membrane (Amersham Hybond-ECL, GE Healthcare) applying a 
constant current of 100V during 3 hours in transfer buffer 1x. Membranes were subsequently 
investigated for Nr3c2 (MR), Scnn1a (α-ENaC), Slc12a3 (NCC) phosphorylated Slc12a3 
(pT53-NCC), Nr3c1 (GR) and β-actin using primary antibodies Nr3c2 (1:100) [14], Scnn1a 
(1:500) [26], Slc12a3 (1:500) (Chemicon), pT53-Slc12a3 (1:1000; Pineda Antibody 
Services), Nr3c1 (1:1000; Santa Cruz, Dallas, TX) β-actin (1:1000; Sigma-Aldrich), anti- 
rabbit IgG secondary antibody (1:10000; Amersham, Burkinghampshire, UK) and anti-mouse 
IgG secondary antibody (1:10000; Jackson Immuno Research, Baltimore, PA). The secondary 
antibodies were coupled with horse Radish Peroxidase (GE Healthcare, millipore) that allows 
the revelation of the proteins by chemiluminescence with ECL reagents (GE Healthcare or 
Pierce, Rockford, IL). Thereby, the membranes were exposed on a photographic film (GE 
Healthcare, millipore) during different times in a cassette (Axon Lab) and developed. The 
films were scanned and the bands intensity was measured using Image Studio Lite Software 
from LI-COR Biosciences. 
Immunofluorescence 
 
Kidneys of anesthetized mice kept under regular salt diet were fixed with 3% 
paraformaldehyde and 0.1% glutaraldehyde in a cacodylate-sucrose buffer as described 
previously [18]. MR was detected by using a primary monoclonal antibody (mouse anti-rat- 
MR rMR1-18 [14], 1:40) incubated overnight at 4°C, and a secondary antibody goat-anti- 
mouse HRP (1:50, Jackson ImmunoResearch). The signal was amplified by using the 
Tyramide Signal Amplification (TSA) System (Perking Elmer). An antigen retrieval treatment 
was performed by microwave during 10 minutes at 98°C in 0.1 M citrate buffer (pH 6). 
Phosphorylated NCC was detected by using a rabbit-anti-mouse pT53NCC antibody [31] 
(1:40000) incubated overnight at 4°C, and a secondary antibody goat-anti-rabbit-CY3 
(1:1000, Jackson ImmunoResearch). Staining was performed on 5µm sections. 
Kidney perfusion and microdissection 
 
Mice were anesthetized by a mixture of Ketamine/Xylazine/Acepromazine (100 mg/kg/ 15 
mg/kg /2.5 mg/kg) injected intraperitoneally. The period of narcosis usually lasts 20-30 min. 
The perfusion is performed into the renal artery by using a catheter. Renal artery perfusion is 
made by 10 ml of DMEM F-12 (Dulbecco'sModified Eagle Medium: Nutrient Mixture F-12) 
followed by 10 ml Liberase (0.9 mg / ml, Liberase Blendzyme 4, Hoffmann-La Roche Inc.). 
Then, kidneys are microdissected as described previously [8]. 2 cm of each segment (PC, PS, 
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TAL, DCT/ CNT and CD) were recovered and processed for relative protein expression 
analysis. The microdissection was performed on 3 experimental and control animals. 
Metabolic Cages Studies 
 
Metabolic balance studies were performed to analyze the renal sodium, potassium and water 
homeostasis under normal sodium, sodium-deficient and high sodium and low potassium 
rescue diet. For time-course analyses, four- to six-week-old control and knockout mice from 
same litter were individually placed into mouse metabolic cages (Tecniplast, Buguggiate, 
Italy) and fed with different salt diets for 6 days. During the experimentation, body weight, 
urine volume, water and food consumption were determined and urine was collected every 
day at the same time. Experimental animals had free access to food and water during the 
experimentations in metabolic cages. 
Regular sodium-diet 
 
23 day-old control and KO mice were individually placed into metabolic cages. Mice were 
fed with a regular-salt diet (0.17% Na+ in the food, Ssniff Spezialdiäten GmbH) during the 6 
days into the metabolic cages. Doxycycline treatment was started from day 2 (25 day-old) and 
applied till the end (day 6) of the metabolic cage study. 
Sodium-deficient diet 
 
25 day-old mice were placed in normal cages and treated with doxycycline for 15 days to 
induce MR-deficiency along the nephron and the collecting duct system. At the end of the 
doxycycline treatment control and KO mice were placed into metabolic cages and fed with a 
regular-salt diet (0.17% Na+ in the food, Ssniff Spezialdiäten GmbH) for 2 days, followed by 
3 days of sodium-deficient diet (0.02% Na+ in the food, Ssniff Spezialdiäten GmbH). 
High sodium and low potassium rescue diet 
 
25 day-old mice were placed in normal cages and treated with doxycycline for 15 days to 
induce MR-deficiency along the nephron and the collecting duct system. During these 15 days 
of doxycycline treatment, mice were fed with a regular sodium diet (0.17% Na+ in the food, 
Ssniff Spezialdiäten GmbH) during the first week, and received a high sodium and low 
potassium rescue diet (3.5% Na+ in the food, Ssniff Spezialdiäten GmbH, and 0.2% K+ in 
drinking water) throughout the second week. At the end of the doxycycline treatment control 
and KO mice were placed into metabolic cages and continued to receive the rescue diet (high 
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Na+ and low K+) and had free access to tap water supplemented with 0.2% of potassium. At 
the end of experimentations, blood samples were collected and mice were sacrificed by 
decapitation. Freshly isolated kidneys were snap-frozen in liquid nitrogen and stored at -80°C 
for further molecular analysis. 
Urine and Plasma analysis 
 
Urine samples (12-24 hours) were collected in metabolic cages. At the end of experiments, 
blood samples were recovered. Urinary and plasma sodium and potassium concentrations 
were measured using the IL943 Flame Photometer (Instrumentation Laboratory, UK). Plasma 
aldosterone levels were measured according to standard procedure using the Coat-A-Count 
RIA kit (Siemens Medical Solutions Diagnostics, Ballerup, Denmark). Moreover, plasma 
corticosterone levels were quantified as previously described [30]. The urinary and plasmatic 
creatinine concentration measurements were performed by enzyme-linked immunosorbent 
assay (ELISA) at the Zurich Integrative Rodent Physiology platform (ZIRP, Zurich, 
Switzerland). 
Determination of 11β-HSD2 Enzyme Activity 
 
11β-HSD2 enzyme activity was measured as previously described [4]. 
 
Statistical Analysis 
 
All measurements were analyzed using the unpaired two-tailed Student’s t-test, considering 
MRPax8/LC1 KO versus control mice, unless differently stated. Data are presented as mean ± 
SEM. Values displaying a p-value smaller than 0.05 were considered as statistically 
significant. *P < 0.05, **P < 0.01, ***P < 0.001 and #P < 0.0001. 
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Results 
 
Generation of inducible nephron-specific MRPax8/LC1 knockout mice 
 
We generated inducible renal tubule-specific MR knockout mice by using the Nr3c2 floxed 
allele (Nr3c2lox/lox [6]), the Pax8-rtTA transgenic mice expressing the reverse tetracycline 
transactivator under the control of the Pax8 promoter that is driving the expression in all 
proximal and distal tubular cells along the nephron [32], and the LC1 transgenic mice where 
the expression of the Cre recombinase and luciferase is under the control of the tetracycline 
response element [28]. The reverse tetracycline transactivator binds and transactivates the 
tetracycline-responsive element in the presence of doxycycline, thereby triggering Cre 
recombinase expression and thus deletion of the floxed allele. We treated 4-week-old 
MRPax8/LC1 triple transgenic animals (carrying the Nr3c2lox/lox, Pax8-rtTAtg/0 and TRE-LC-1tg/0 
transgenes and named MRPax8/LC1) and their control littermates (Nr3c2lox/lox; Pax8-rtTAtg/0, 
Nr3c2lox/lox;TRE-LC-1tg/0, and Nr3c2lox/lox named MRPax8, MRLC1 and MRlox respectively) with 
doxycycline to induce the deletion of the Nr3c2 gene locus in adult mice. Quantitative mRNA 
expression measurement of MR revealed a 80% decrease in MRPax8/LC1 knockout mice 
(Fig.1A), and Western blot analyses showed a 90% reduction of Nr3c2 protein expression 
upon doxycycline treatment in the whole kidney (Fig.1B and C). Western blot analyses of 
microdissected nephron segments confirmed wild-type MR expression in the distal nephron, 
namely the thick ascending limb (TAL), distal convoluted tubule (DCT), connecting tubule 
(CNT), and in the cortical collecting ducts (CCD) in control mice, and demonstrated near- 
absence of MR protein expression in the corresponding segments of the MRPax8/LC1 knockout 
mice (Fig.1D and Supplementary Fig. 1). The glucocorticoid receptor GR, the Na-K-Cl 
cotransporter NKCC2, the sodium-chloride symporter NCC, and the cytoplasmic Ca2+- 
binding protein calbindin CB28 were used as markers of the different nephron segments 
(Fig.1D). A strong reduction in MR expression in the MRPax8/LC1 knockout mice could also be 
demonstrated by immunofluorescence (Fig. 1E). Pax8 expression has been described also in 
the liver [32], but we observed no changes of MR protein expression in this organ (Fig.1F and 
G). 
Adult nephron-specific MRPax8/LC1 knockout mice develop a PHA-1 phenotype under a 
regular sodium diet 
We monitored the body weight of MRPax8/LC1 knockout and control animals fed with a regular 
salt diet. MRPax8/LC1  knockout mice rapidly stopped to gain body weight, whereas control 
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animals kept gaining weight (Fig. 2A) following the doxycycline induction. To determine 
urinary and plasma Na+ and K+ concentrations, we placed control and knockout animals into 
metabolic cages and performed measurements every 12 hours to evaluate the cyclicity of 
sodium, potassium and water excretion. MRPax8/LC1 knockout mice exhibited increased urine 
volume output and urinary Na+ excretion under a standard salt diet (Fig. 2B and C), while the 
urinary K+ excretion did not change (Fig. 2D). Interestingly, these differences are obvious 
only during the activity period (night) (Fig. 2B and D). The fractional excretion of K+ did not 
vary between the two groups, while the fractional excretion of Na+ was significantly increased 
in the knockouts (Fig. 2E and F) confirming that the increase in urinary sodium excretion 
reported in Figure 2C is not transient, but sustained upon regular sodium diet several weeks 
after MR deletion in renal tubules. MRPax8/LC1 knockout animals also presented with 
significantly lower natremia but still within the physiological range (135-145 mmol/l), and 
hyperkalemia (Fig. 3A, B). We observed no difference in food intake (Supplementary Table 
1), and in plasma corticosterone levels (Fig. 3C). Urine creatinine concentration did not vary 
among the two groups (Supplementary Fig. 3A), however, plasma creatinine concentration 
was significantly higher (Supplementary Fig. 3B) and the creatinine clearance significantly 
reduced (Supplementary Fig. 3C) in the knockout animals indicating that kidney function is 
affected by the loss of MR in renal tubules. Moreover, plasma aldosterone levels markedly 
increased in the MRPax8/LC1  knockouts (Fig. 3D) mimicking a severe PHA-1 phenotype. 
The PHA-1 phenotype becomes lethal under a sodium-deficient diet 
 
The shift to a diet deficient in Na+ caused a further decrease in the body weight of the 
knockout animals (Fig. 4A) leading to 100% death after three days of diet shift (n=9 
MRPax8/LC1 knockouts). Water and food consumption did not change (Supplementary Table 1), 
however urine volume and urinary Na+ excretion was increased and urinary K+ excretion was 
significantly reduced in the MRPax8/LC1 knockout animals (Fig. 4B-D) that also presented with 
hyponatremia and hyperkalemia (Fig. 5A and B). Plasma corticosterone levels in the 
knockout animals increased following the shift from a regular Na+ diet to a Na+-deficient diet 
(Fig. 5C). Plasma aldosterone further increased in the MRPax8/LC1 knockout mice under a 
sodium-deficient diet (Fig. 5D) to reach extraordinary high levels (40 nM) a concentration 
that should occupy 100% of MR and a significant proportion (about 20%) of GR [12]. 
13	 
High Na+ and low K+ diet restores body weight and electrolyte balance in MRPax8/LC1 
knockout mice 
To counterbalance for Na+ loss and reduced K+ excretion, nephron-specific MRPax8/LC1 
knockout mice were subjected to a diet rich in Na+ and low in K+ during two weeks. Indeed, 
the knockout animals restored body weight gain compared to controls following high Na+ and 
low K+ treatment (Fig. 6A). Food and water intake (Supplementary Table 1), urinary and 
plasma Na+ and K+ concentrations and urine volume were indistinguishable between the two 
groups (Fig. 6B-D and Fig. 7A and B) but plasma aldosterone levels of MRPax8/LC1 knockout 
animals remained significantly higher following high Na+ and low K+ diet (Fig. 7C). Thus, 
solely a diet rich in Na+ and low in K+ allows the MRPax8/LC1 knockout mice to develop 
normally and to restore urine and plasma electrolytes. 
Increased GR expression in the MRPax8/LC1 knockout mice 
 
Being both expressed in the ASDN, GR and MR have been proposed to have opposing 
effects, suggesting that activated GR can partially but not completely compensate for the loss 
of MR function [27,29,5,23]. We thus analysed GR protein expression in the kidney of 
MRPax8/LC1 knockout mice by Western blot analyses. We found a moderate but significant 
increase in the protein expression of GR under normal Na+ diet (Fig. 8A and B). This increase 
was less obvious at the cellular level, as revealed by immunofluorescence analyses, and may 
be restricted to specific cell types (data not shown). Under Na+-deficient diet GR protein 
expression was about four-times significantly increased in the knockouts (Fig. 8C and D) 
indicating that MR deletion leads to increased renal expression of GR. This increase could be 
restored following the rescue (high Na+ / low K+) diet (Fig. 8E and F). Furthermore, mRNA 
levels of the 11β-hydroxysteroid dehydrogenase (Hsd11b2) and renin (Ren-1c) were 
significantly increased in the kidney of MRPax8/LC1 knockout mice under both normal and Na+- 
deficient diets (Supplementary Fig. 2A-D), however the activity of the enzyme 11β- 
hydroxysteroid dehydrogenase type 2 (Hsd11b2) did not vary (Supplementary Fig. 2E). 
Decreased NCC activity in the MRPax8;LC1 knockout mice despite severe salt-losing 
syndrome 
To study whether the absence of MR in adult kidney might regulate the expression and 
function of sodium-transporting proteins, we analysed NCC and ENaC protein expression 
following induction of MR-deficiency under standard, Na+-deficient and rescue (high Na+ / 
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low K+) diets. MRPax8/LC1 knockout mice presented with a significant decrease in the levels of 
total and phosphorylated NCC, and this decrease was even more pronounced under a Na+- 
deficient diet (Fig. 9A-D), but less important under the rescue diet (Fig. 9E and F). 
Immunofluorescence staining of perfused kidneys also revealed a decreased phospho-NCC 
expression in MRPax8/LC1 knockout mice under a standard salt diet (Fig. 9G). The level of the α 
subunit of ENaC was also significantly reduced in the knockout animals (Fig. 9A-F). 
Altogether, these data indicate that the absence of MR in the nephron leads to NCC 
downregulation despite the increased sodium loss. 
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Discussion 
 
We focused our study on the acute deletion of MR along the entire nephron and the collecting 
ducts of adult animals by using the Pax8-rtTA/LC-1 double transgenic mice [32]. MRPax8/LC1 
knockout mice present failure to thrive as a result of increased renal loss of sodium and water. 
The mutant mice also show highly increased plasma aldosterone levels on both standard and 
Na+-deficient diets developing a severe pseudohypoaldosteronism syndrome with rapid 
weight loss, disturbance of plasma Na+ and K+ concentrations, significantly increased urinary 
Na+ loss and decreased K+ excretion (Fig. 2-5). The phenotype observed in the MRPax8/LC1 
knockout mice is more severe than that observed in mice deficient for MR in renal principal 
cells in which inactivation of MR in CD and late CNT does not affect Na+ balance under 
standard conditions [23,24]. The results presented in this article clearly demonstrate that MR 
deficiency in the nephron during adulthood cannot be compensated by sodium transporting 
proteins upstream of late CNT (NCC [13]) or downstream along the CD (electroneutral 
sodium chloride reabsorption [10]), and that MR expression either in the TAL, DCT, or 
intercalated cells is crucial to maintain Na+ and K+ homeostasis. 
Both MR and GR are expressed in the distal renal tubular cells [1] and can bind and be 
activated by the mineralocorticoid aldosterone and the glucocorticoid cortisol (corticosterone 
in mice and rats), respectively [17,12]. However, GR can also be bound and activated by 
aldosterone [12], which is a relatively weak GR agonist with a Ki  of 140 nM [22]. 
Aldosterone stimulates also the transcriptional activity of GR at high concentrations [22]. Yet, 
in the MRPax8/LC1 knockouts plasma aldosterone rises to a maximum of 40 nM (Fig. 3D and 
5D). MR can also be bound and activated by cortisol (corticosterone in mice and rats), but 
since physiological glucocorticoids circulate in the blood at 100-1000 higher concentration 
than aldosterone, rapid conversion of cortisol to cortisone by the enzyme 11β-hydroxysteroid 
dehydrogenase type 2 (11βHSD2) allows aldosterone to selectively activate MR in epithelial 
tissues. In vitro and in vivo experimental models show that GR might play a role in renal 
sodium transport [3] being implicated in compensatory [5] or cooperative [12] mechanisms 
along with MR, and we thus hypothesized that GR in MRPax8/LC1 knockout mice might 
compensate at least partially for the loss of MR. We found however no compensatory action 
of GR on MR in the context of renal salt transport, in spite of an overall increased GR protein 
expression in the kidney of the MRPax8/LC1 knockout mice (Fig. 8A and B) that could not be 
confirmed by immunohistochemistry under a regular salt diet (data not shown) and the 
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increased plasma corticosterone levels of the knockouts following the shift to a Na+-deficient 
diet (Fig. 5C). 
Sodium reabsorption in the aldosterone-responsive distal tubular segments is mediated by the 
amiloride-sensitive epithelial sodium channel ENaC expressed in the principal cells of the CD 
and CNT, together with the thiazide-sensitive sodium-chloride co-transporter NCC in the 
DCT [25]. Described as the “aldosterone paradox”, aldosterone can either trigger Na+ 
reabsorption in the DCT via the Na+/Cl- co-transporter NCC and ENaC in DCT2, CNT and 
CD following a hypovolemic challenge, or increase NaCl delivery by inhibiting NCC activity 
in DCT responding to an hyperkalemic challenge. This results in differential regulation of Na+ 
and K+  transport between the DCT and the ASDN [2]. Aldosterone can activate ENaC 
through MR by inhibiting Nedd4-2 via phosphorylation by serum- and glucocorticoid-induced 
kinase 1 (Sgk1) [9], but aldosterone-activated MR can also bind to the promoter region of the 
gene encoding the α subunit of ENaC leading to de novo synthesis of this channel [33]. We 
found a reduction in the expression of the αENaC protein in MRPax8/LC1 deficient mice under 
normal, low-Na+ and high-Na+ / low-K+ rescue diets, showing that ENaC expression is under 
the control of MR (Fig. 9). As the knockout animals suffer from Na+ wasting, they could be in 
a hypovolemic state, and thus both hypovolemia and hyperkalemia may be present in the 
mutant animals. Aldosterone, which is highly increased in the knockouts, should activate 
NCC, but NCC is significantly less expressed and phosphorylated in the MRPax8/LC1 mice (Fig. 
9). This finding is surprising, as the MRPax8/LC1 mice suffer from hyponatremia accompanied 
by high plasma aldosterone levels, and is consistent with the notion that the hyperkalaemic 
challenge dominates the hypovolemic stimulus in the context of the aldosterone paradox. We 
also found surprising no decreased K+ excretion under a standard diet (Fig. 2F) linked with 
hyperkalemia. This result was confirmed by three independent series of experiments (data not 
shown) and by measurements of urinary K+ fractional excretion (Fig. 2F). One possible 
explanation could be a reduced but still sufficient ENaC activity to allow normal urinary K+ 
excretion. However, this unchanged urinary K+ excretion in the MRPax8/LC1 knockout mice is 
not sufficient to avoid the establishment of the hyperkalemic status. 
Targeted inactivation of MR in the whole nephron and the collecting duct system with the 
exception of the glomeruli cannot be compensated on a standard diet by activation of the 
RAAS, which is reflected by upregulation of Ren-1c expression in the kidney and the 
increased aldosterone levels in the blood of the MRPax8/LC1 knockout mice (Suppl. Fig. 2 and 
Fig. 2 and 5). The decrease of NCC expression and phosphorylation (Fig. 9) might be induced 
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in an attempt to increase the Na+ delivery to the CNT and CD where ENaC is normally highly 
expressed, allowing the exchange of Na+ against K+. Thus, apical electrogenic ENaC- 
mediated transepithelial Na+ reabsorption allows the excretion of K+ from principal cells to 
the primary urine. However, inward Na+ and outward K+ transcellular fluxes are impaired in 
the MRPax8/LC1 knockout mice. Indeed, increased plasma aldosterone levels cannot activate 
MR in the MRPax8/LC1 knockouts, and thus aldosterone cannot trigger de novo synthesis of 
ENaC and ensure the channel stability at the apical membrane via the Sgk1 pathway. 
In conclusion, the MRPax8/LC1 knockout mice fully reproduce the human PHA-1 phenotype, 
ENaC expression is dependent on MR activity and hyperkalemia is probably the main 
complication to be avoided even at the expense of increased Na+ excretion. 
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Figure legends 
 
Figure 1 Characterization of inducible renal tubule-specific MRPax8/LC1 KO mice. (A) 
Quantification of Nr3c2 mRNA expression relative to β-actin in whole kidney of MRPax8/LC1 
KO mice and their control littermates (n = 4 per genotype). (B) Analysis of MR protein 
expression by Western blot analysis in whole kidney lysates. β-actin was used as loading 
control (n = 4 per genotype). (C) Quantification of MR protein expression relative to β-actin 
of panel B. (D) Representative analysis of MR protein expression by Western blot analysis 
from microdissected renal tubules. PCT, proximal convoluted tubule; PST, proximal straight 
tubule; TAL, thick ascending limb; DCT, distal convoluted tubule; CNT, connecting tubule; 
CCD, cortical collecting duct. GR expressed throughout the whole nephron, NKCC2 as 
marker of the TAL, NCC solely expressed in the DCT and CNT, and CB28 as a distal marker 
of the nephron were used to define the different nephron segments. (E) Representative 
analysis of MR protein expression by immunofluorescence from total kidney under regular 
sodium diet (n = 4 per genotype). (F) Analysis of MR protein expression by Western blot 
analysis in whole liver lysates in KO (n = 5) and control mice (n = 6). (G) Quantification of 
MR protein expression in the liver relative to β-actin of panel E. 
Figure 2 Weight loss, increased urine volume and urinary sodium excretion under 
regular sodium diet. 
(A) Body weight of MRPax8/LC1 KO and control mice before and following doxycycline 
treatment (n = 7 per genotype). (B, C and D) Time course for 12-h urine volume (B), urinary 
sodium excretion (C), urinary potassium excretion (D), fractional excretion (FE) of Na+ (n = 
5-6 per genotype) (E) and fractional excretion of K+ (n = 7 per genotype) (F) determined in 
metabolic cages for MRPax8/LC1 KO and control mice under regular sodium diet. 
Figure 3 Decreased plasma sodium levels, hyperkalemia and increased plasma 
aldosterone levels under normal salt diet. 
(A) Plasma sodium and (B) potassium concentrations in MRPax8/LC1 KO (n = 7) and control (n 
= 9) mice following 4 days of doxycycline treatment. (C) Plasma corticosterone and (D) 
aldosterone levels measured in KO (n = 8-11) and control (n = 8-11) animals following 15 
days and 4 days of doxycycline treatment, respectively. RS: regular sodium diet, 0.17% Na+ 
in food. 
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Figure 4 Continuous body weight loss and decreased urinary potassium excretion upon 
sodium-deficient diet. 
(A) Body weight under standard salt diet followed by a sodium-deficient diet. KO (n = 9) and 
controls (n = 8). (B, C and D) Time course for 12-h urine volume (B), urinary sodium 
excretion (C) and urinary potassium excretion (D) determined in metabolic cages in KO (n = 
9) and control (n = 8) animals receiving a sodium-deficient diet. 
 
Figure 5 Hyponatremia, hyperkalemia and highly increased plasma aldosterone levels 
under sodium-deficient diet. 
(A) Plasma sodium and (B) potassium concentrations following 15 days of doxycycline 
treatment. KO (n = 12) and controls (n = 15). (C) Plasma corticosterone and (D) plasma 
aldosterone levels following 15 days of doxycycline treatment. (n = 8-9 per genotype). RS, 
regular sodium diet, 0.17% Na+ in food; SD, sodium-deficient diet, 0.02% Na+ in food. **P< 
0.01, KO under Na+-deficient versus KO under regular Na+ diet. 
Figure 6 Restoration of body weight and urinary electrolytes upon high sodium and low 
potassium (rescue) diet. 
(A) Body weight of MRPax8/LC1 KO and control mice upon high sodium and low potassium 
diet (n = 11 per genotype). (B, C and D) Time course for 24-h urine volume (B), urinary 
sodium excretion (C) and urinary potassium excretion (D) determined in metabolic cages for 
MRPax8/LC1 KO and control mice under a high sodium and low potassium diet (n = 5 per 
genotype). 
Figure 7 Restoration of plasma electrolytes upon high sodium and low potassium 
(rescue) diet. 
(A) Plasma sodium and (B) potassium concentrations in MRPax8/LC1 KO (n = 6) and control (n 
= 5) mice under a high sodium and low potassium diet. (C) Plasma aldosterone levels 
measured in KO (n = 6) and control (n = 5) animals under a high sodium and low potassium 
diet. Measurements were performed following 15 days of doxycycline treatment and 15 days 
of rescue diet. 
Figure 8 Increased GR protein levels upon regular and sodium-deficient diets. (A) 
Representative Western blot analysis of GR and β-actin in whole kidney lysates under a 
regular sodium diet (n = 6 per genotype). (B) Graph shows quantification of Western blots for 
20	 
GR from 2 independent experiments. (C) Representative Western blot analysis of GR and β- 
actin in whole kidney lysates under a sodium-deficient diet (n = 6 per genotype). (D) Graph 
shows quantification of Western blots in C. (E) Representative Western blot analysis of GR 
and β-actin in whole kidney lysates under a rescue (high Na+ / low K+) diet (n ≥ 5 per 
genotype). (F) Graph shows quantification of Western blots in E. 
Figure 9 Downregulation of NCC and α-ENaC protein expression. 
 
(A) Representative Western blot analysis for total NCC, phosphorylated pT53-NCC and α- 
ENaC in kidney lysates from mice kept under regular sodium diet. β-actin was used as 
loading control (n = 6 per genotype). (B) Graphs show quantification of Western blots for 
NCC, pT53-NCC and α-ENaC from 2 independent experiments and normalized to β-actin (n 
= 7 per genotype). KO and control animals were kept upon regular sodium diet and proteins 
were extracted from the whole kidney. (C) Western blot analysis for total NCC, 
phosphorylated pT53-NCC and α-ENaC in kidney lysates from mice kept under sodium- 
deficient diet during three days. β-actin was used as loading control (n = 4 per genotype). (D) 
Graphs show quantification of Western blots for NCC, pT53-NCC and α-ENaC from 2 
independent experiments and normalized to β-actin (n = 7 per genotype). KO and control 
animals were kept upon sodium-deficient diet and proteins were extracted from the whole 
kidney. (E) Western blot analysis for total NCC, phosphorylated pT53-NCC and α-ENaC in 
kidney lysates from mice kept under high Na+ / low K+ rescue diet. β-actin was used as 
loading control (n ≥ 5 per genotype). (F) Graphs show quantification of Western blots in E. 
(G) Analysis of phospho-NCC protein expression by immunofluorescence from total kidney 
(n = 4 per genotype) upon regular sodium diet. 
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